Brain RVD-haemopressin, a haemoglobin-derived peptide, inhibits bombesin-induced central activation of adrenomedullary outflow in the rat

Br J Pharmacol. 2014 Jan;171(1):202-13. doi: 10.1111/bph.12471.

Abstract

Background and purpose: Haemopressin and RVD-haemopressin, derived from the haemoglobin α-chain, are bioactive peptides found in brain and are ligands for cannabinoid CB1 receptors. Activation of brain CB1 receptors inhibited the secretion of adrenal catecholamines (noradrenaline and adrenaline) induced by i.c.v. bombesin in the rat. Here, we investigated the effects of two haemoglobin-derived peptides on this bombesin-induced response

Experimental approach: Anaesthetised male Wistar rats were pretreated with either haemoglobin-derived peptide, given i.c.v., 30 min before i.c.v. bombesin and plasma catecholamines were subsequently measured electrochemically after HPLC. Direct effects of bombesin on secretion of adrenal catecholamines were examined using bovine adrenal chromaffin cells. Furthermore, activation of haemoglobin α-positive spinally projecting neurons in the rat hypothalamic paraventricular nucleus (PVN, a regulatory centre of central adrenomedullary outflow) after i.c.v. bombesin was assessed by immunohistochemical techniques.

Key results: Bombesin given i.c.v. dose-dependently elevated plasma catecholamines whereas incubation with bombesin had no effect on spontaneous and nicotine-induced secretion of catecholamines from chromaffin cells. The bombesin-induced increase in catecholamines was inhibited by pretreatment with i.c.v. RVD-haemopressin (CB1 receptor agonist) but not after pretreatment with haemopressin (CB1 receptor inverse agonist). Bombesin activated haemoglobin α-positive spinally projecting neurons in the PVN.

Conclusions and implications: The haemoglobin-derived peptide RVD-haemopressin in the brain plays an inhibitory role in bombesin-induced activation of central adrenomedullary outflow via brain CB1 receptors in the rat. These findings provide basic information for the therapeutic use of haemoglobin-derived peptides in the modulation of central adrenomedullary outflow.

Keywords: bombesin; brain; cannabinoid CB1 receptor; central adrenomedullary outflow; haemoglobin-derived peptides.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenal Medulla / drug effects*
  • Adrenal Medulla / innervation*
  • Adrenal Medulla / metabolism
  • Animals
  • Bombesin / administration & dosage
  • Bombesin / pharmacology*
  • Cannabinoid Receptor Agonists / administration & dosage
  • Cannabinoid Receptor Agonists / pharmacology*
  • Cattle
  • Cells, Cultured
  • Chromaffin Cells / drug effects
  • Chromaffin Cells / metabolism
  • Dose-Response Relationship, Drug
  • Drug Inverse Agonism
  • Epinephrine / blood*
  • Epinephrine / metabolism
  • Hemoglobins / administration & dosage
  • Hemoglobins / pharmacology*
  • Injections, Intraventricular
  • Male
  • Norepinephrine / blood*
  • Norepinephrine / metabolism
  • Paraventricular Hypothalamic Nucleus / drug effects*
  • Paraventricular Hypothalamic Nucleus / metabolism
  • Peptide Fragments / administration & dosage
  • Peptide Fragments / pharmacology*
  • Rats
  • Rats, Wistar
  • Receptor, Cannabinoid, CB1 / agonists
  • Receptor, Cannabinoid, CB1 / metabolism
  • Spinal Nerves / drug effects*
  • Spinal Nerves / metabolism
  • Time Factors

Substances

  • Cannabinoid Receptor Agonists
  • Cnr1 protein, rat
  • Hemoglobins
  • Peptide Fragments
  • RVD-hemopressin, human
  • Receptor, Cannabinoid, CB1
  • hemopressin
  • Bombesin
  • Norepinephrine
  • Epinephrine